Bacterial vaginosis and menopause are tangled together in ways that confuse both patients and clinicians. The drop in estrogen that accompanies menopause reshapes the vaginal microbiome so thoroughly that standard diagnostic tools for BV may not even work reliably in postmenopausal women, and the symptoms of BV can look almost identical to the normal vaginal changes menopause brings. A systematic review and meta-analysis estimated BV prevalence among postmenopausal women at roughly 17%, though the true figure is uncertain because the tests used were never validated for this age group.1PubMed. Prevalence of bacterial vaginosis in postmenopausal women: a systematic review and meta-analysis The relationship between the two conditions is more complicated, and more clinically consequential, than most people realize.
How Menopause Reshapes the Vaginal Environment
Before menopause, estrogen drives the vaginal lining to thicken and deposit glycogen, a form of stored sugar. Lactobacillus bacteria feed on that glycogen and produce lactic acid, which keeps vaginal pH low (acidic) and discourages the overgrowth of organisms linked to BV. When estrogen levels decline during the menopausal transition, this whole chain weakens. A comparison of pre- and postmenopausal women found that free glycogen levels in vaginal samples dropped dramatically after menopause, and Lactobacillus counts tracked closely with glycogen in both groups.2PubMed Central. An exploratory comparison of vaginal glycogen and Lactobacillus levels in pre- and post-menopausal women
The result is a fundamental shift in the microbial neighborhood. A study comparing premenopausal and postmenopausal Korean women using genetic sequencing confirmed that Lactobacillus taxa were reduced more than any other group after menopause, and lactic acid concentrations in vaginal fluid fell alongside them.3PubMed Central. Changes in the Microbiome of Vaginal Fluid after Menopause in Korean Women Vaginal pH rises, and microbial diversity increases, meaning more types of bacteria move in as Lactobacillus loses its hold.4PubMed Central. Menopausal Changes in the Microbiome-A Review Focused on the Genitourinary Microbiome This is a normal consequence of declining estrogen, not automatically a sign of infection. But it creates an environment where BV-associated bacteria can establish themselves more easily.
The Changes Start Before Menopause Officially Arrives
Perimenopause, the years of irregular periods leading up to the final menstrual period, is not a holding pattern. The estrogen fluctuations during this phase are enough to destabilize the vaginal microbiome well before menopause is formally reached. Research by Brotman and colleagues found that perimenopausal women were significantly more likely to have vaginal communities not dominated by Lactobacillus compared to premenopausal women, and women with even mild vulvovaginal atrophy had dramatically higher odds of carrying a community type associated with BV-like conditions.5IntechOpen. Vaginal Microbiome in Perimenopause and Postmenopause: Dysbiosis, Genitourinary Syndrome and Novel Therapeutic Approaches If you are in perimenopause and noticing new vaginal symptoms, the microbiome shift may have already begun.
Why Diagnosing BV After Menopause Is Unreliable
Here is where the science gets genuinely messy. The two standard diagnostic approaches for BV, the Amsel clinical criteria and the Nugent Gram-stain score, were both developed and validated in premenopausal women. Both rely heavily on detecting low Lactobacillus levels and elevated pH as markers of BV. The problem is that postmenopausal women naturally have low Lactobacillus and elevated pH because of estrogen loss, not because of BV. A postmenopausal woman could score “positive” for BV on these tests simply because she is postmenopausal.
Research examining which bacteria actually correlate with high Nugent scores in postmenopausal women found a very different picture from younger women. In premenopausal women, a high Nugent score reliably indicates the presence of classic BV-associated organisms like Gardnerella and Atopobium. In postmenopausal women, only Prevotella was consistently associated with high scores, and other BV-associated genera were absent. The researchers concluded bluntly that high Nugent scores should not be used to infer BV in postmenopausal women.6PubMed Central. Bacterial Communities Associated With Abnormal Nugent Score in Postmenopausal Versus Premenopausal Women
This diagnostic gap has real consequences. The reported prevalence of BV in postmenopausal women ranges wildly, from 2% to 57%, and this enormous spread is likely driven partly by overdiagnosis using tools that do not account for the normal postmenopausal state.7PubMed Central. Bacterial Vaginosis in Postmenopausal Women One older study that carefully classified women by menopausal status actually found a lower rate of BV in postmenopausal women (about 6%) compared to premenopausal women (about 10%), regardless of whether they were on hormone therapy.8PubMed Central. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women The honest answer is that nobody knows the true BV rate in postmenopausal women with much confidence, because the measuring tools are flawed for this group.
When BV Looks Like Menopause and Menopause Looks Like BV
The overlap between BV and the genitourinary syndrome of menopause (GSM, the umbrella term for vaginal dryness, irritation, urinary symptoms, and tissue thinning caused by low estrogen) creates a diagnostic minefield for clinicians. Both conditions can produce vaginal discharge, odor, discomfort, and a pH above 5. Both involve reduced Lactobacillus. A survey of clinician practices found that some diagnostic features of BV and GSM overlap substantially, and that validated commercial molecular tests for BV have not been confirmed to work accurately in women over 50.9Menopause. Bacterial vaginosis diagnosis and treatment in postmenopausal women: A survey of clinician practices
This is why experts increasingly recommend a “treat the estrogen deficiency first” approach. If a postmenopausal woman presents with vaginal symptoms and an elevated pH, the recommended first step is to address the underlying estrogen loss, typically with low-dose vaginal estrogen. If symptoms persist after the vaginal environment has been restored, then a BV diagnosis and targeted antibiotic treatment become more meaningful.10PubMed Central. Bacterial Vaginosis in Postmenopausal Women Jumping straight to antibiotics for what looks like BV but is actually estrogen-driven atrophy is one of the most common missteps.
What Happens to the Microbiome When You Restore Estrogen
Low-dose vaginal estrogen therapy can produce striking changes. In one study of 30 women treated for atrophic vaginitis, the proportion of Lactobacillus in vaginal bacterial communities jumped from about 11% to 71% after treatment, and BV-associated bacteria such as Gardnerella, Prevotella, and Atopobium dropped sharply.11Scientific Reports. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis Hormone replacement therapy more broadly has been shown to support Lactobacillus dominance and resolve vaginal symptoms.12PubMed. Menopause and the vaginal microbiome
That said, the relationship between hormones and the microbiome is not entirely straightforward. A randomized, placebo-controlled trial of systemic hormone therapy (as opposed to local vaginal estrogen) found that while treated women experienced meaningful symptom relief and improved vaginal tissue health, no significant differences were seen in actual microbial composition or diversity compared to placebo.13PubMed. The effect of hormone therapy on vaginal microbiota in women with genitourinary syndrome of menopause This suggests that systemic hormone therapy may improve symptoms through tissue effects rather than by fully restoring the premenopausal microbiome. Local vaginal estrogen appears to have a more direct and measurable impact on the vaginal bacterial population.
Options When Hormones Are Off the Table
Not everyone can or wants to use estrogen. Breast cancer survivors, women with estrogen-sensitive conditions, and those who simply prefer non-hormonal approaches need alternatives. Several have been studied with varying degrees of rigor.
Vaginal pH-lowering gels have shown promise. In a randomized trial of breast cancer survivors who had undergone menopause after cancer treatment, a pH-balanced vaginal gel significantly lowered vaginal pH and improved dryness and discomfort compared to placebo.14Obstetrics & Gynecology. Vaginal pH-Balanced Gel for the Control of Atrophic Vaginitis Among Breast Cancer Survivors Polycarbophil-based vaginal gels have also demonstrated the ability to bring pH down significantly and maintain lower pH for days after a single application, along with improvements in signs of BV.15Current Therapeutic Research. Effect on vaginal pH of a polycarbophil vaginal gel compared with an acidic douche in women with suspected bacterial vaginosis
Products containing live Lactobacillus strains are another option. A pilot randomized trial found that a vaginal lubricant gel containing Lactobacillus reduced both vaginal pH and pathogenic bacteria in postmenopausal women more effectively than a control product.16PLoS ONE. Evaluation of the efficacy of Lactobacillus-containing feminine hygiene products on vaginal microbiome and genitourinary symptoms in pre- and postmenopausal women Oral and vaginal probiotics, particularly strains like Lactobacillus rhamnosus and Lactobacillus acidophilus, have been proposed to colonize the vaginal epithelium and produce lactic acid, hydrogen peroxide, and other antimicrobial compounds that help restore the acidic environment. The evidence base here is still developing. Pilot studies look encouraging, but large randomized trials confirming long-term benefits in postmenopausal women are thin on the ground.
The Emotional and Sexual Toll
BV after menopause is not just a clinical curiosity. A cross-sectional study of Australian postmenopausal women who had experienced BV found that roughly half reported recurrences, distress, and a negative impact on their sexual relationships.17Sexual Health. Bacterial vaginosis after menopause: factors associated and women’s experiences The specifics are revealing: 89% reported abnormal odor or discharge that caused them distress, about half felt self-conscious, and nearly half said BV had affected a sexual relationship, with a third of those saying they tried to avoid sex altogether.18Sexual Health. Bacterial vaginosis after menopause: factors associated and women’s experiences
These numbers are striking because postmenopausal BV is often discussed in purely clinical terms, as a question of microbiology and pH. For the women experiencing it, the condition intersects with already-fraught territory: body image after menopause, sexual confidence, and the worry that a partner will notice something wrong. The study also found that BV in postmenopausal women was associated with sexual activity, which means avoiding sex (a common coping strategy) may reduce exposure but does not address the underlying microbial disruption.
The Link to Urinary Tract Infections
The vaginal microbiome is not a closed system. The bacteria living in the vagina directly influence what colonizes the urinary tract, because the anatomical proximity means organisms can migrate easily. When Lactobacillus levels drop, as they do during and after menopause, urinary pathogens gain a foothold more readily. A review of the relationship between vaginal dysbiosis and urinary tract infections concluded that decreased vaginal Lactobacillus, as seen with menopause, correlates with an increased presence of urinary pathogens and greater susceptibility to UTI, and that interventions to restore vaginal ecology could reduce UTI burden.19PubMed Central. The Vaginal Microbiome and Recurrent and Chronic Urinary Tract Infection
If you are postmenopausal and dealing with recurrent UTIs, the vaginal microbiome is worth paying attention to. Restoring vaginal Lactobacillus, whether through vaginal estrogen or other means, may address both vaginal symptoms and urinary susceptibility in one step. Many women cycle through repeated courses of antibiotics for UTIs without anyone evaluating the vaginal environment that may be feeding the problem.
How Diabetes Adds Another Layer
Type 2 diabetes, which becomes more common after menopause, can compound the microbiome disruption. A study of perimenopausal and postmenopausal women with type 2 diabetes found that higher fasting blood glucose and hemoglobin A1c levels were negatively correlated with key Lactobacillus species. As blood sugar markers rose, the relative abundance of protective Lactobacillus crispatus, Lactobacillus gasseri, and Lactobacillus iners all decreased significantly.20PubMed Central. Peculiarities of vaginal microbiota in perimenopausal and postmenopausal women with type 2 diabetes mellitus
This means postmenopausal women with poorly controlled diabetes face a double hit to their vaginal ecology: the estrogen-driven reduction in glycogen and Lactobacillus, plus a metabolic environment that further suppresses whatever protective bacteria remain. If you are managing both menopause and type 2 diabetes, blood sugar control may have implications for vaginal health that your endocrinologist and gynecologist are not connecting.
The Inflammation Side of the Story
The microbial shift after menopause does not just open the door to infection. It also changes the vaginal immune landscape. Research measuring inflammatory markers in vaginal fluid found that both pro-inflammatory and anti-inflammatory cytokine levels were significantly higher in postmenopausal women compared to premenopausal women, and that these cytokine levels correlated directly with Lactobacillus levels.21GREM Gynecological and Reproductive Endocrinology & Metabolism. Lactobacillus species and inflammatory cytokine profile in the vaginal milieu of pre-menopausal and post-menopausal women The postmenopausal vaginal environment, in other words, is not just less acidic and less Lactobacillus-rich. It is also more inflamed. This low-grade inflammation may contribute to the tissue discomfort and susceptibility to infection that characterize the postmenopausal vagina, and it adds another reason why restoring the microbial balance, rather than treating individual infections in isolation, may matter for long-term vaginal health.
Why Humans Are Unusual in the First Place
One detail that researchers find genuinely puzzling is that the Lactobacillus-dominated vaginal microbiome is a human oddity. When comparing across primate species, reproductive-age humans show distinctly Lactobacillus-heavy vaginal communities, unlike other primates whose vaginal bacteria are far more diverse.22PubMed. The primate vaginal microbiome: comparative context and implications for human health and disease This suggests that the protective Lactobacillus shield humans maintain during reproductive years is an evolutionary adaptation, possibly linked to the unusually long human pregnancy and the high cost of reproductive tract infections during gestation. When menopause removes the hormonal foundation for this adaptation, the vaginal microbiome does not revert to some diseased state. It shifts toward something closer to what most primates carry all their lives. Research in older captive primates has found BV-associated bacteria primarily in multiparous animals at ages comparable to human perimenopause, suggesting the hormonal decline and microbial shift are shared across closely related species.23Scientific Reports. Vaginal Dysbiosis from an Evolutionary Perspective
This evolutionary framing does not mean postmenopausal vaginal symptoms should be dismissed or accepted passively. But it does reframe what is happening: menopause is not “breaking” the vaginal microbiome. It is removing the conditions that maintained a uniquely human adaptation. Understanding this distinction matters because it points away from treating every postmenopausal microbiome as pathological and toward supporting the environment in ways that reduce symptoms and prevent genuine infections while respecting the biology of the transition.